July 29, 2010 10:19 AM Eastern Daylight Time

Study Analysis Identifies Potential Biomarkers of VELCADE (Bortezomib) Activity in Patients with Relapsed Mantle Cell Lymphoma

-- Data suggest possibility of more targeted approach to treatment with VELCADE--

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company today reported new correlative science data from the pivotal PINNACLE trial of VELCADE® (bortezomib) in patients with relapsed/refractory...

admin

Public release date: 12-Jul-2010

Findings by the John Theurer Cancer Center may lead to more targeted clinical trials and therapies

HACKENSACK, N.J. (July 12, 2010) — A new study by researchers from the John Theurer Cancer Center at Hackensack University Medical Center sheds light on how bortezomib (VELCADE®), the first in a new class of cancer drugs known as proteasome inhibitors, works in mantle cell lymphoma. The study also provides preliminary evidence for which...

admin

EMEA Approves Update to Velcade(R) (bortezomib) Label to Include Survival Benefit in Previously Untreated Patients with Multiple Myeloma

BEERSE, Belgium, June 15, 2010 /PRNewswire/ --

- Additional Data Demonstrating Efficacy of bortezomib Presented at the 15th Congress of the European Hematology Association

Janssen-Cilag today welcomes the approval by the European Commission of the update to the Summary of Product Characteristics (SmPC) for Velcade(R) (bortezomib)...

admin

June 05, 2010 06:15 PM Eastern Daylight Time

Data from Pomalidomide Study in Refractory Multiple Myeloma Patients Presented at ASCO

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ: CELG) today announced results of a Phase II study of pomalidomide and dexamethasone in multiple myeloma patients who have failed both lenalidomide and bortezomib. Data were presented by Dr. Martha Lacy of the Mayo Clinic during the American Society of Clinical Oncology...

admin

May 10, 2010 03:00 AM Eastern Daylight Time

--Takeda Continues to Build Global Presence in Oncology--

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (“Takeda,” TSE:4502) and its wholly owned subsidiary Millennium: The Takeda Oncology Company (“Millennium”) today announced that Takeda has entered into a co-promotion agreement with Janssen Pharmaceutical K.K. (“Janssen Pharma”) for VELCADE® (bortezomib) for Injection, a treatment...

admin